Carcinoma of Unknown Primary with EML4‐ALK Fusion Response to ALK Inhibitors

With the advent of next‐generation sequencing (NGS) and precision medicine, investigators have determined that tumors from different tissue sources that have the same types of genetic mutations will have a positive response to the same targeted therapy. This finding has prompted us to seek potential...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncologist
Hauptverfasser: Zhao, Peng, Peng, Ling, Wu, Wei, Zheng, Yi, Jiang, Weiqin, Zhang, Hangyu, Tong, Zhou, Liu, Lulu, Ma, Ruobing, Wang, Liping, Yao, Ming, Wang, Kai, Fang, Weijia, Wu, Liming
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley & Sons, Inc. 2019
Schlagworte:
Precision Medicine Clinic: Molecular Tumor Board
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6459257/
https://ncbi.nlm.nih.gov/pubmed/30679319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0439
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge